Serum Institute of India — Contact Email, Phone & Team

Overview

Serum Institute of India (SII), established in 1966, is a prominent Indian multinational biotechnology and biopharmaceutical company headquartered in Pune, Maharashtra. It is renowned as the world's largest vaccine manufacturer by volume, producing over 1.3 billion doses annually. SII's extensive portfolio includes vaccines, biopharmaceuticals, generic drugs, and over-the-counter medications, serving approximately 170 countries worldwide. The company is a subsidiary of the Cyrus Poonawalla Group, with Adar Poonawalla serving as the CEO. SII's investment strategy is multifaceted, encompassing both internal development and external partnerships. In April 2023, through its subsidiary Serum Institute Life Sciences (SILS), SII doubled its investment in Biocon Biologics to $300 million, enhancing access to 100 million vaccine doses annually and distribution rights to SII's vaccine portfolio. This strategic alliance aims to bolster global vaccine availability and affordability. Additionally, in May 2024, SII acquired a 20% stake in IntegriMedical, a med-tech firm specializing in needle-free injection systems, aligning with SII's mission to make healthcare accessible and affordable. This partnership seeks to revolutionize vaccine administration by reducing needle-stick injuries and improving patient comfort. SII's investment philosophy emphasizes rapid response to global health challenges and technological innovation. The company has a proven track record of swiftly addressing infectious disease outbreaks, exemplified by its prompt delivery of investigational vaccines during the 2022 Sudan ebolavirus outbreak in Uganda. Furthermore, SII's collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) aims to enhance the production of affordable outbreak vaccines, contributing to global preparedness against future pandemics. Through these strategic investments and partnerships, SII continues to advance its mission of providing life-saving vaccines and medical solutions to populations worldwide.

Investment Focus

Strategic alignment with SII's mission to provide affordable healthcare solutions
Innovative technologies in vaccine development and delivery
Potential for global impact in public health
Strong management teams with a track record of success
Scalable business models with clear pathways to profitability
Commitment to quality and regulatory compliance
Ability to navigate complex international markets
Alignment with SII's ethical standards and corporate values
Potential for long-term partnerships and collaborations
Demonstrated need for financial support to achieve growth objectives

Portfolio Companies

Biocon BiologicsIntegriMedicalDharma Productions

Get the full list of 54,000+ investors

Serum Institute of India and every other firm and angel in the database — as one spreadsheet you keep.

$19one-time payment · no subscription

All 54,000+ investors — VC firms, private equity, family offices and angels
The key person to contact at each one, with their job title
Their work email address
Their phone number
Their LinkedIn profile
Delivered as a single .xlsx file — download it as many times as you like

Get the full list — $19 → One payment. No seats, no credits, no expiry. Already bought it? Sign in to download it again — no second payment.

Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.

Frequently asked questions about Serum Institute of India

What sectors does Serum Institute of India invest in?

Serum Institute of India invests in Technology, Healthcare, Real Estate, Education, Agriculture and Food and Beverage, and is based in Maharashtra, India. Serum Institute of India is listed as a corporate vc in the ConnectSafely investor database.